4.5 Review

Risks and benefits of oral modified-release compared with oral immediate-release opioid use after surgery: a systematic review and meta-analysis

Journal

ANAESTHESIA
Volume 78, Issue 10, Pages 1225-1236

Publisher

WILEY
DOI: 10.1111/anae.16085

Keywords

acute pain; modified-release; opioid; surgery

Categories

Ask authors/readers for more resources

The use of modified-release opioids for acute postoperative pain is common, but it may increase the risk of adverse effects. This systematic review and meta-analysis aimed to assess the safety and efficacy of modified-release compared to immediate-release oral opioids in adults with postoperative pain. The review included randomized clinical trials and observational studies that compared these two types of opioids. The results showed that modified-release opioids were associated with higher incidence of adverse events and worse pain compared to immediate-release opioids. The study concluded that modified-release opioids were not superior in terms of analgesic consumption, hospital stay, hospital readmission, or physical function after surgery. One study found that modified-release opioids were linked to higher rates of persistent postoperative opioid use. No studies reported on psychological function, costs, or quality of life.
Prescription of modified-release opioids for acute postoperative pain is widespread despite evidence to show their use may be associated with an increased risk of adverse effects. This systematic review and meta-analysis aimed to examine the available evidence on the safety and efficacy of modified-release, compared with immediate-release, oral opioids for postoperative pain in adults. We searched five electronic databases from 1 January 2003 to 1 January 2023. Published randomised clinical trials and observational studies on adults who underwent surgery which compared those who received oral modified-release opioids postoperatively with those receiving oral immediate-release opioids were included. Two reviewers independently extracted data on the primary outcomes of safety (incidence of adverse events) and efficacy (pain intensity, analgesic and opioid use, and physical function) and secondary outcomes (length of hospital stay, hospital readmission, psychological function, costs, and quality of life) up to 12 months postoperatively. Of the eight articles included, five were randomised clinical trials and three were observational studies. The overall quality of evidence was low. Modified-release opioid use was associated with a higher incidence of adverse events (n = 645, odds ratio (95%CI) 2.76 (1.52-5.04)) and worse pain (n = 550, standardised mean difference (95%CI) 0.2 (0.04-0.37)) compared with immediate-release opioid use following surgery. Our narrative synthesis concluded that modified-release opioids showed no superiority over immediate-release opioids for analgesic consumption, length of hospital stay, hospital readmissions or physical function after surgery. One study showed that modified-release opioid use is associated with higher rates of persistent postoperative opioid use compared with immediate-release opioid use. None of the included studies reported on psychological function, costs or quality of life.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available